

General Law Committee JOINT FAVORABLE REPORT

Bill No.: SB-1006

AN ACT CONCERNING REVISIONS TO THE PHARMACY AND DRUG

Title: CONTROL STATUTES.

Vote Date: 3/21/2019

Vote Action: Joint Favorable Substitute

PH Date: 3/12/2019

File No.:

***Disclaimer:** The following JOINT FAVORABLE Report is prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and does not represent the intent of the General Assembly or either chamber thereof for any purpose.*

SPONSORS OF BILL:

General Law Committee

REASONS FOR BILL:

The reason for this bill is to make multiple revisions to the pharmacy and drug control statutes of the DCP. Language is updated regarding US Pharmacopeia sterile compounding standards to ensure pharmacy conformance. Pharmacies would be required to report if they are a subject of legal action. There is also a change in the temporary state designation of controlled substances for 240 days by virtue of federal action to permanently align with federal classification. This would obviate the Drug Control Division from having to continually comb the DEA final rulings for revisions to the regulations to conform to federal scheduling of a drug. DCP also would be allowed to reclassify FDA approved marijuana based medicine to the classification the DEA designates. The changes in this bill are technical and some are to provide the DCP tools necessary ensure the health and safety of the public.

Proposed Substitute Language

Section 1 :(4) was added to state "USP chapters means 797, 800 and 825 of US Pharmacopia pertaining to compounding sterile pharmaceuticals and their referenced companion documents, as amended from time to time.

Substitute language added "USP chapters" and most "recent" version in several areas of proposed substitute language.

RESPONSE FROM ADMINISTRATION/AGENCY:

Seagull, Michele, Commissioner, Department of Consumer Protection

SB 1006 is a DCP bill and the DCP appreciates the General Law Committee for considering the bill.

SB 1006 makes multiple technical changes and provides the Drug Control Division additional tools to protect public health and safety.

NATURE AND SOURCES OF SUPPORT:

Connecticut Hospital Association

CHA appreciates the importance of ensuring that pharmacies that handle compound sterile drugs and medications for patients operate with appropriate care and safety. Given the massive guidance in the USP document, the bill fails to meet basic standards for informing pharmacists that are subject to the law about what is reasonably expected of them. This would be a regulatory burden and increase costs to hospitals. Therefore, CHA opposes Section 1 of this bill.

CHA takes no action on Section 2 as it does not apply to Connecticut hospitals. CHA supports Section 3 and 4.

NATURE AND SOURCES OF OPPOSITION:

None Expressed

Reported by: Bonnie Gray, Asst. Clerk

Date: 04/01/2019